Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL6232155 | 0.94 | AKR1B1 (0.52) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| Ethylene Glycol SCHEMBL6229361 | 0.94 | AKR1B1 (0.52) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| 1,3-Propanediol SCHEMBL6335045 | 0.91 | AKR1B1 (0.48) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL5341838 | 0.89 | AKR1B1 (0.47) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL70565 | 0.84 | AKR1B1 (0.71) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| Hydrochloric Acid SCHEMBL8922940 | 0.82 | AKR1B1 (0.68) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL8986802 | 0.82 | ALDH1A1 (0.39) | AKR1B1CYP1A2CYP2C19POLBALDH1A1 | |
| SCHEMBL3360788 | 0.80 | KEAP1 (0.61) | — | |
| SCHEMBL2353171 | 0.79 | FOLH1 (0.60) | AKR1B1CYP1A2CYP2C19LMNAGAA | |
| SCHEMBL4402323 | 0.78 | AKR1B1 (0.62) | AKR1B1CYP1A2CYP2C19LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4826888-A | STORAGE STABLE, DISCOLORATION INHIBITION | MITSUBISHI RAYON CO., LTD. (JP) | 1989-05-02 | — | — | US | claimed |
| US-20230152696-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230152696-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4083029-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| CN-105980353-B | ROR gamma modulators | 领先制药控股公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004072022-A1 | COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-08-26 | — | — | WO | disclosed |
| WO-2003106550-A2 | ORGANIC THIOL METAL-FREE STABILIZERS AND PLASTICIZERS FOR HALOGEN-CONTAINING POLYMERS | THE COLLEGE OF WILLIAM AND MARY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030220429-A1 | Organic thiol metal-free stabilizers and plasticizers for halogen-containing polymers | COLLEGE OF WILLIAM AND MARY, THE | 2003-11-27 | — | — | US | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | AKR1B1 1687/4885CYP1A2 1890/4885CYP2C19 2865/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | AKR1B1 1046/4885CYP1A2 1655/4885CYP2C19 3627/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | AKR1B1 966/4885CYP1A2 1737/4885CYP2C19 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.